This issue of the Journal of Human Hypertension contains papers based on work presented at and arising from an Official Satellite Workshop of the International Society of Hypertension on 'Hypertension in Transplant Recipients' held in London in June 1996. Jenkins and Singer (pp 813-823) describe the broad range of candidate mechanisms underlying abnormalities in blood pressure after transplantation, including de novo hypertension, increased severity of pre-existing high blood pressure and loss of the normal night-time fall in blood pressure. Plasma levels of the cardiac natriuretic peptides ANP and BNP are markedly elevated after heart transplantation. Buckley et al (pp 825-826) report on the circulating forms of these peptides in heart transplant recipients. Whereas ANP was detected circulating only as the low molecular weight C-terminal ANP 99-126 form, BNP was found to circulate both as low and high molecular weight forms. Additional recent work from this group and others has suggested that plasma BNP may potentially be of particular value as a non-invasive test of cardiac function because of prolonged stability at room temperature. Although cyclosporin A and tacrolimus commonly cause hypertension, studies by Sussman et al 2 have shown that these immunophilin-stabilising immunosuppressive drugs can also prevent some forms of experimental cardiac hypertrophy by reducing activation of calcineurin, a calcium-regulated phosphatase which stimulates growth factor expression in T cells and in cardiac myocytes. These fascinating recent studies may provide clues to new therapeutic options for cardiac hypertrophy both in association with hypertension after transplantation as well as complicating other forms of heart disease.
